Skip to main content
ENDO 2026 Main banner

Topic: Pediatric and Adolescent Endocrinology
Session Type: Symposium

SY52 - Growth Disorders: Emerging Insights and Innovative Therapeutic Approaches

Monday, June 15, 2026
4:30 PM - 6:00 PM CT
Location: Room W187

    Symposium Chair(s)

  • Alexsandra Malaquias, PhD (she/her/hers)

    Professor
    Faculdade de Ciencias Medicas da Santa Casa de Sao Paulo
    Sao Paulo, Brazil

    Disclosure(s): No financial relationships to disclose

  • Andrew Dauber, MD (he/him/his)

    Chief of Endocrinology
    Children's National Hospital
    Washington, DC, United States

    Disclosure(s): Ascendis: Clinical Trial Investigator (), Consultant (); BioMarin: Advisory Board (), Clinical Trial Investigator (), Consultant (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (), Grant Recipient (); Eton Pharmaceutical: Consultant (); Lumos: Clinical Trial Investigator (); Neurocrine: Clinical Trial Investigator (); Novo Nordisk: Clinical Trial Investigator (), Consultant (); Pfizer Inc: Advisory Board (), Clinical Trial Investigator (), Consultant (), Grant Recipient (); QED Pharmaceutical: Advisory Board (), Clinical Trial Investigator (), Consultant (); Sandoz: Consultant ()

Disclosure(s):
Alexsandra Malaquias, PhD: No financial relationships to disclose
Andrew Dauber, MD, MMSc: Ascendis: Clinical Trial Investigator (), Consultant (); BioMarin: Advisory Board (), Clinical Trial Investigator (), Consultant (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (), Grant Recipient (); Eton Pharmaceutical: Consultant (); Lumos: Clinical Trial Investigator (); Neurocrine: Clinical Trial Investigator (); Novo Nordisk: Clinical Trial Investigator (), Consultant (); Pfizer Inc: Advisory Board (), Clinical Trial Investigator (), Consultant (), Grant Recipient (); QED Pharmaceutical: Advisory Board (), Clinical Trial Investigator (), Consultant (); Sandoz: Consultant ()

Growth disorders are among the leading consultations with pediatric endocrinologists due to their potential impact on children's health. The etiology of growth disorders is multiple and heterogeneous, leading to distinct strategies and scenarios depending on the subjacent cause. Despite the long experience with daily growth hormone, novelties on growth-promoting therapies have emerged recently. This session will adresss current knowledge and therapeutic advances on distinct clinical settings of growth failure, emphasizing the best practice for pediatric patients care.

Presentations:

  • 4:30 PM - 5:00 PM CT
    Addressing Complexities, Evidence, and Opportunities of Current Pediatric Growth Hormone Treatment

    Symposium Speaker: Paulo Collett-Solberg, MD – UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO

  • 5:00 PM - 5:30 PM CT
    New Implications in the Endocrine Care of Achondroplasia

    Symposium Speaker: Nadia Merchant, MD, FAAP, FACMG – UT SOUTHWESTERN MEDICAL CENTER

  • 5:30 PM - 6:00 PM CT
    Imprinting Disorders and Growth Failure: Optimizing the Role of Growth-Promoting Therapies

    Symposium Speaker: Irene Netchine, MD,PhD – Hopital Trousseau